---
title: "Seaport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294683039.md"
datetime: "2026-08-03T11:05:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294683039.md)
  - [en](https://longbridge.com/en/news/294683039.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294683039.md)
---

# Seaport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -1.78.

EBIT: As of FY2026 Q2, the actual value is USD -62.35 M.

Seaport Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026, on August 3, 2026.

#### Cash Position

As of June 30, 2026, Seaport Therapeutics, Inc.’s cash, cash equivalents, and investments totaled $427.3 million, an increase from $233.7 million as of December 31, 2025. The company raised $260.0 million in gross proceeds from its upsized IPO in May 2026.

#### Operating Expenses

##### Research and Development (R&D) Expenses

R&D expenses for the second quarter of 2026 were $24.6 million, an increase of $11.2 million from $13.4 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $46.0 million, up from $23.9 million for the six months ended June 30, 2025.

##### General and Administrative (G&A) Expenses

G&A expenses for the second quarter of 2026 were $41.2 million, a significant increase of $36.1 million from $5.1 million in the second quarter of 2025, primarily due to one-time, non-cash stock-based compensation costs related to the IPO. For the six months ended June 30, 2026, G&A expenses were $47.3 million, compared to $10.7 million for the six months ended June 30, 2025.

##### Total Operating Expenses

Total operating expenses for the second quarter of 2026 were $65.8 million, compared to $18.5 million for the second quarter of 2025. For the six months ended June 30, 2026, total operating expenses were $93.4 million, up from $34.7 million for the six months ended June 30, 2025.

#### Net Loss

Seaport Therapeutics, Inc. reported a net loss of - $62.6 million for the second quarter of 2026, an increase from a net loss of - $15.1 million for the second quarter of 2025, mainly due to the aforementioned stock-based compensation costs. The net loss for the six months ended June 30, 2026, was - $88.0 million, compared to - $28.2 million for the same period in 2025.

#### Balance Sheet Data (as of June 30, 2026 vs. December 31, 2025)

-   Working capital: $266.5 million vs $210.4 million.
-   Total assets: $441.7 million vs $249.0 million.
-   Total stockholders’ equity (deficit): $422.6 million vs - $92.5 million.

#### Outlook / Guidance

Seaport Therapeutics, Inc. expects its cash, cash equivalents, and investments to fund operations into 2029. This cash runway is anticipated to support multiple key clinical data readouts, including topline data from the Phase 2b BUOY-1 trial of GlyphAllo in MDD in the first half of 2027 and the Phase 1 driving simulation trial in the second half of 2026. Additionally, the company plans to initiate Phase 2a and Phase 2b trials for GlyphAgo in GAD in the second half of 2026 and first half of 2027, respectively, with topline data expected in early 2028 and by year-end 2028.

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [YSX Tech files Form 3 initial beneficial ownership statement for director Wu Jifeng](https://longbridge.com/en/news/296394699.md)
- [Baosheng Media files Form 3 initial beneficial ownership statement for CEO, director Lina Jiang](https://longbridge.com/en/news/296507606.md)
- [Rocket Companies director Sarah Watterson files Form 3 initial beneficial ownership statement](https://longbridge.com/en/news/296141298.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [Solventum files Form 3 for SVP, Controller and CAO Neil Zieselman](https://longbridge.com/en/news/296265352.md)